Sign In
Buy ABBV
$227.23
+2.30 (+1.02%)
At Close: Jun 05, 2026
AbbVie (ABBV) Q4 Earnings Beat, Raises Sales View for Key Drugs
02:06pm, Friday, 02'nd Feb 2024
AbbVie???s (ABBV) fourth-quarter earnings and sales beat estimates. Management hikes the 2027 forecast for new immunology drugs to more than $27 billion.
AbbVie Inc. (ABBV) Q4 2023 Earnings Call Transcript
01:00pm, Friday, 02'nd Feb 2024
AbbVie Inc. (ABBV) Q4 2023 Earnings Call Transcript
Nonfarm Payrolls Increased More Than Expected
11:46am, Friday, 02'nd Feb 2024
The big jobs numbers out this week came from this morning's U.S. Bureau of Labor Statistics' (BLS) Employment Situation report, which surprised to the upside in a major way: 353K new jobs created for
Bristol Meyers Squibb, AbbVie top 4Q sales and profit estimates
11:32am, Friday, 02'nd Feb 2024
Drugmakers Bristol-Myers Squibb Co (NYSE:BMY, ETR:RM, OTC:BMYMP) and Abbvie Inc (NYSE:ABBV) on Friday both reported better than expected financial results for the December quarter, sending shares of b
BLS Jobs Up Big: 353K, 3.7% Unemployment
11:26am, Friday, 02'nd Feb 2024
353K new jobs created for January are nearly double the 180K or so analysts were looking for.
AbbVie (ABBV) Reports Q4 Earnings: What Key Metrics Have to Say
11:01am, Friday, 02'nd Feb 2024
The headline numbers for AbbVie (ABBV) give insight into how the company performed in the quarter ended December 2023, but it may be worthwhile to compare some of its key metrics to Wall Street estima
AbbVie turns a corner; patent cliff fears were overblown
10:16am, Friday, 02'nd Feb 2024
AbbVie NYSE: ABBV is turning an important corner in 2024 and is on track to resume growth. Its Humira-related patent cliff aside, the business is stronger than ever, and the patent cliff is more of a
4 Large Drug Stocks Trying to Survive the Industry Challenges
09:51am, Friday, 02'nd Feb 2024
Drug and biotech companies are likely to see significant innovation. In the Large-Cap Pharmaceuticals industry, Eli Lilly (LLY), Novo Nordisk (NVO), AbbVie (ABBV) and Novartis (NVS) are worth retainin
AbbVie (ABBV) Q4 Earnings and Revenues Top Estimates
09:46am, Friday, 02'nd Feb 2024
AbbVie (ABBV) came out with quarterly earnings of $2.79 per share, beating the Zacks Consensus Estimate of $2.76 per share. This compares to earnings of $3.60 per share a year ago.
AbbVie Posts Revenue Beat as Humira Sales Tumble. Other Immunology Drugs Are Selling.
08:40am, Friday, 02'nd Feb 2024
AbbVie raises its fiscal 2027 sales expectations for Skyrizi and Rinvoq.
AbbVie posts less-than-healthy financial results for 2023
07:46am, Friday, 02'nd Feb 2024
Pharmaceuticals company AbbVie (NYSE: ABBV) reported its Q4 and full year financial results for 2023 this afternoon. The American medical R&D powerhouse had some setbacks in the year, including disapp
AbbVie's fourth-quarter sales top estimates despite plunging Humira revenues
07:40am, Friday, 02'nd Feb 2024
AbbVie Inc. ABBV, +1.94% on Friday reported fourth-quarter sales that topped analysts' estimates, even as it faces low-cost competition for its top-selling drug, Humira.
Wall Street Favorites: 3 Biotech Stocks With Strong Buy Ratings for January 2024
12:03pm, Wednesday, 31'st Jan 2024
There is a lot of good news to digest from the biotech sector. Not only does it offer lots of strong stocks in January, but it is also expected to grow rapidly.
Unveiling AbbVie (ABBV) Q4 Outlook: Wall Street Estimates for Key Metrics
10:21am, Tuesday, 30'th Jan 2024
Evaluate the expected performance of AbbVie (ABBV) for the quarter ended December 2023, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics
3 Stocks Enjoying Favorable Analyst Coverage
07:11pm, Monday, 29'th Jan 2024
We see daily analyst upgrades and downgrades, coming with price targets. They can be helpful tools for investors, providing a more structured plan and helping to inject positivity surrounding future p
